Abstract
The anti-platelet drug clopidogrel has been shown to modulate adhesion molecule and cytokine expression, both playing an important role in the pathogenesis of atherosclerosis. The aim of this study was to investigate the impact of clopidogrel on the development and progression of atherosclerosis. ApoE−/− mice fed an atherogenic diet (cholesterol: 1 %) for 6 months received a daily dose of clopidogrel (1 mg/kg) by i.p. injection. Anti-platelet treatment was started immediately in one experimental group, and in another group clopidogrel was started 2 month after beginning of the atherogenic diet. Blood was analysed at days 30, 60 and 120 to monitor the lipid profile. After 6 months the aortic arch and brachiocephalic artery were analysed by Sudan IV staining for plaque size and by morphometry for luminal occlusion. Serum levels of various adhesion molecules were investigated by ELISA and the cellular infiltrate was analysed by immunofluorescence. After daily treatment with 1 mg/kg clopidogrel mice showed a significant reduction of atherosclerotic lesions in the thoracic aorta and within cross sections of the aortic arch [plaque formation 55.2 % (clopidogrel/start) vs. 76.5 % (untreated control) n = 8, P < 0.05]. After treatment with clopidogrel P-/E-selectin levels and cytokine levels of MCP-1 and PDGFβ were significantly reduced as compared to controls. The cellular infiltrate showed significantly reduced macrophage and T-cell infiltration in clopidogrel-treated animals. These results show that clopidogrel can effectively delay the development and progression of ‘de-novo’ atherosclerosis. However, once atherosclerotic lesions were already present, anti-platelet treatment alone did not result in reverse remodelling of these lesions.
Similar content being viewed by others
Abbreviations
- ADP:
-
Adenosine diphosphate
- OCT:
-
Optimal cutting temperature
- DC:
-
Dendritic cells
References
CAPRIE Steering Committee (1996) A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet 348(9038):1329–1339
Sabatine MS, Cannon CP, Gibson CM, Lopez-Sendon JL, Montalescot G, Theroux P, Claeys MJ, Cools F, Hill KA, Skene AM, McCabe CH, Braunwald E (2005) Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation. N Engl J Med 352(12):1179–1189
Ohkubo K, Fujimoto Y, Iwata Y, Kitahara H, Kadohira T, Sugimoto K, Morino T, Kobayashi Y (2014) Efficacy and safety of low-dose clopidogrel in Japanese patients after drug-eluting stent implantation: a randomized pilot trial. Heart Vessels 29(1):1–6
Massberg S, Brand K, Gruner S, Page S, Muller E, Muller I, Bergmeier W, Richter T, Lorenz M, Konrad I, Nieswandt B, Gawaz M (2002) A critical role of platelet adhesion in the initiation of atherosclerotic lesion formation. J Exp Med 196(7):887–896
Massberg S, Schurzinger K, Lorenz M, Konrad I, Schulz C, Plesnila N, Kennerknecht E, Rudelius M, Sauer S, Braun S, Kremmer E, Emambokus NR, Frampton J, Gawaz M (2005) Platelet adhesion via glycoprotein IIb integrin is critical for atheroprogression and focal cerebral ischemia: an in vivo study in mice lacking glycoprotein IIb. Circulation 112(8):1180–1188
Herbert JM (2004) Effects of ADP-receptor antagonism beyond traditional inhibition of platelet aggregation. Expert Opin Investig Drugs 13(5):457–460
Solheim S, Pettersen AA, Arnesen H, Seljeflot I (2006) No difference in the effects of clopidogrel and aspirin on inflammatory markers in patients with coronary heart disease. Thromb Haemost 96(5):660–664
Azar RR, Kassab R, Zoghbi A, Aboujaoude S, El-Osta H, Ghorra P, Germanos M, Salame E (2006) Effects of clopidogrel on soluble CD40 ligand and on high-sensitivity C-reactive protein in patients with stable coronary artery disease. Am Heart J 151(2):521 e521–521 e524
Abele S, Spriewald BM, Ramsperger-Gleixner M, Wollin M, Hiemann NE, Nieswandt B, Weyand M, Ensminger SM (2009) -A35) Attenuation of transplant arteriosclerosis with clopidogrel is associated with a reduction of infiltrating dendritic cells and macrophages in murine aortic allografts. Transplantation 87(2):207–216
Eckl S, Heim C, Abele-Ohl S, Hoffmann J, Ramsperger-Gleixner M, Weyand M, Ensminger SM (2010) Combination of clopidogrel and everolimus dramatically reduced the development of transplant arteriosclerosis in murine aortic allografts. Transpl Int 23(9):959–966
Heim C, Eckl S, Gebhardt J, Weyand M, Ensminger SM (2010) Die unterschätzte Rolle von Thrombozyten bei der Herztransplantation. Zeitschrift für Herz-, Thorax- und Gefäßchirurgie 24(4):241–250
Rathouska J, Nemeckova I, Zemankova L, Strasky Z, Jezkova K, Varejckova M, Nachtigal P (2015) Cell adhesion molecules and eNOS expression in aorta of normocholesterolemic mice with different predispositions to atherosclerosis. Heart Vessels 30(2):241–248
Afek A, Kogan E, Maysel-Auslender S, Mor A, Regev E, Rubinstein A, Keren G, George J (2009) Clopidogrel attenuates atheroma formation and induces a stable plaque phenotype in apolipoprotein E knockout mice. Microvasc Res 77(3):364–369
Schulz C, Konrad I, Sauer S, Orschiedt L, Koellnberger M, Lorenz R, Walter U, Massberg S (2008) Effect of chronic treatment with acetylsalicylic acid and clopidogrel on atheroprogression and atherothrombosis in ApoE-deficient mice in vivo. Thromb Haemost 99(1):190–195
Abele S, Weyand M, Wollin M, Hiemann NE, Harig F, Fischlein T, Ensminger SM (2006) Clopidogrel reduces the development of transplant arteriosclerosis. J Thorac Cardiovasc Surg 131(5):1161–1166
Jacobi J, Maas R, Cardounel AJ, Arend M, Pope AJ, Cordasic N, Heusinger-Ribeiro J, Atzler D, Strobel J, Schwedhelm E, Boger RH, Hilgers KF (2010) Dimethylarginine dimethylaminohydrolase overexpression ameliorates atherosclerosis in apolipoprotein E-deficient mice by lowering asymmetric dimethylarginine. Am J Pathol 176(5):2559–2570
Ensminger SM, Billing JS, Morris PJ, Wood KJ (2000) -E18) Development of a combined cardiac and aortic transplant model to investigate the development of transplant arteriosclerosis in the mouse. J Heart Lung Transplant 19(11):1039–1046
Overbergh L, Giulietti A, Valckx D, Decallonne R, Bouillon R, Mathieu C (2003) The use of real-time reverse transcriptase PCR for the quantification of cytokine gene expression. J Biomol Tech 14(1):33–43
Nishiyama T, Mishima K, Obara K, Inoue H, Doi T, Kondo S, Saka M, Tabunoki Y, Hattori Y, Kodama T, Tsubota K, Saito I (2007) Amelioration of lacrimal gland inflammation by oral administration of K-13182 in Sjogren’s syndrome model mice. Clin Exp Immunol 149(3):586–595
Yamamoto T, Nakahata Y, Tanaka M, Yoshida M, Soma H, Shinohara K, Yasuda A, Mamine T, Takumi T (2005) Acute physical stress elevates mouse period1 mRNA expression in mouse peripheral tissues via a glucocorticoid-responsive element. J Biol Chem 280(51):42036–42043
Lusis AJ (2000) Atherosclerosis. Nature 407(6801):233–241
Ross R (1999) Atherosclerosis–an inflammatory disease. N Engl J Med 340(2):115–126
Kher N, Marsh JD (2004) Pathobiology of atherosclerosis–a brief review. Semin Thromb Hemost 30(6):665–672
Gawaz M, Langer H, May AE (2005) Platelets in inflammation and atherogenesis. J Clin Invest 115(12):3378–3384
Moura R, Tjwa M, Vandervoort P, Van Kerckhoven S, Holvoet P, Hoylaerts MF (2008) Thrombospondin-1 deficiency accelerates atherosclerotic plaque maturation in ApoE−/− mice. Circ Res 103(10):1181–1189
Ait-Oufella H, Salomon BL, Potteaux S, Robertson AK, Gourdy P, Zoll J, Merval R, Esposito B, Cohen JL, Fisson S, Flavell RA, Hansson GK, Klatzmann D, Tedgui A, Mallat Z (2006) Natural regulatory T cells control the development of atherosclerosis in mice. Nat Med 12(2):178–180
Mor A, Planer D, Luboshits G, Afek A, Metzger S, Chajek-Shaul T, Keren G, George J (2007) Role of naturally occurring CD4+ CD25+ regulatory T cells in experimental atherosclerosis. Arterioscler Thromb Vasc Biol 27(4):893–900
Heim C, Eckl S, Preidl R, Ramsperger-Gleixner M, Koch N, Goldmann K, Spriewald BM, Weyand M, Ensminger SM (2015) Delayed therapy with clopidogrel and everolimus prevents progression of transplant arteriosclerosis and impairs humoral alloimmunity in murine aortic allografts. Eur J Cardiothorac Surg 47(1):180–187
Burger PC, Wagner DD (2003) Platelet P-selectin facilitates atherosclerotic lesion development. Blood 101(7):2661–2666
Li G, Sanders JM, Bevard MH, Sun Z, Chumley JW, Galkina EV, Ley K, Sarembock IJ (2008) CD40 ligand promotes Mac-1 expression, leukocyte recruitment, and neointima formation after vascular injury. Am J Pathol 172(4):1141–1152
Lindemann S, Kramer B, Seizer P, Gawaz M (2007) Platelets, inflammation and atherosclerosis. J Thromb Haemost 5(Suppl 1):203–211
Gawaz M, Neumann FJ, Dickfeld T, Koch W, Laugwitz KL, Adelsberger H, Langenbrink K, Page S, Neumeier D, Schomig A, Brand K (1998) Activated platelets induce monocyte chemotactic protein-1 secretion and surface expression of intercellular adhesion molecule-1 on endothelial cells. Circulation 98(12):1164–1171
Cybulsky MI, Iiyama K, Li H, Zhu S, Chen M, Iiyama M, Davis V, Gutierrez-Ramos JC, Connelly PW, Milstone DS (2001) A major role for VCAM-1, but not ICAM-1, in early atherosclerosis. J Clin Invest 107(10):1255–1262
Boring L, Gosling J, Cleary M, Charo IF (1998) Decreased lesion formation in CCR2−/− mice reveals a role for chemokines in the initiation of atherosclerosis. Nature 394(6696):894–897
Libby P (2002) Inflammation in atherosclerosis. Nature 420(6917):868–874
Wood KJ, Goto R (2012) Mechanisms of rejection: current perspectives. Transplantation 93(1):1–10
Conflict of interest
There are no conflicting financial interests, research support was obtained from the ELAN and IZKF -trust of the University of Erlangen-Nuernberg and the ADUMED-foundation, and no other funding source was employed.
Ethical standard
The study protocol was approved by the local animal research ethics committee and was conducted in accordance with the Helsinki Declaration.
Author information
Authors and Affiliations
Corresponding author
Additional information
C. Heim and J. Gebhardt have contributed equally to this work.
Rights and permissions
About this article
Cite this article
Heim, C., Gebhardt, J., Ramsperger-Gleixner, M. et al. Clopidogrel significantly lowers the development of atherosclerosis in ApoE-deficient mice in vivo. Heart Vessels 31, 783–794 (2016). https://doi.org/10.1007/s00380-015-0696-7
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00380-015-0696-7